deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03768492

Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy (ReDCoAT)

A Phase 1, Randomized, Double Blinded, Placebo Controlled Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy

Sponsor: NYU Langone Health

Conditions Carcinoma Breast
Interventions Caffeine anhydrous 5% added to Lipoderm Cream Base. Lipoderm Cream Base
Updated 13 times since 2019 Last updated: Jul 28, 2025 Started: Jun 29, 2020 Primary completion: Dec 31, 2025 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Carcinoma Breast and is currently ongoing. NYU Langone Health leads this study, which shows 13 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Mar 2022 · 12 months · monthly snapshot~Mar 2022 – ~Feb 2023 · 11 months · monthly snapshot~Feb 2023 – ~Nov 2023 · 9 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Aug 2025 · 10 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

13 versions recorded

  1. Aug 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Oct 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 8 earlier versions

  1. Feb 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  2. Mar 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  3. Mar 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  5. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Jun 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

  7. Feb 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE2

  8. Jan 2019 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NYU Langone Health
Data source: NYU Langone Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations